Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1995-05-26
1997-11-18
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
540581, A61K 3155, C07D47108
Patent
active
056887892
ABSTRACT:
The invention relates to thereof. The invention also relates to the use of such compounds for the treatment or prevention of neuronal loss in ischemia, hypoxia, brain or spinal chord trauma, as well as for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome.
REFERENCES:
patent: 3310565 (1967-03-01), Galantay
patent: 3361767 (1968-01-01), Dobson et al.
patent: 3403156 (1968-09-01), Humber et al.
patent: 3403157 (1968-09-01), Himber et al.
patent: 3426015 (1969-02-01), Dobson et al.
patent: 3458518 (1969-07-01), Dobson et al.
patent: 3487075 (1969-12-01), Davis et al.
patent: 3491088 (1970-01-01), Dobson et al.
patent: 3493560 (1970-02-01), Dobson et al.
patent: 3509134 (1970-04-01), Davis et al.
patent: 3542787 (1970-11-01), Dobson et al.
patent: 3597433 (1971-08-01), Dobson et al.
patent: 3641038 (1972-02-01), Davis et al.
patent: 3716541 (1973-02-01), Dobson et al.
patent: 3717641 (1973-02-01), Kocsis et al.
patent: 3812119 (1974-05-01), Walker
patent: 3892756 (1975-07-01), Nedelec et al.
patent: 4009273 (1977-02-01), Nedelec et al.
patent: 4052508 (1977-10-01), Anderson et al.
patent: 4064139 (1977-12-01), Anderson et al.
patent: 4148898 (1979-04-01), Koch et al.
patent: 4232158 (1980-11-01), Shepard et al.
patent: 4374838 (1983-02-01), Anderson et al.
patent: 4399141 (1983-08-01), Anderson et al.
patent: 4465677 (1984-08-01), DeMarinis et al.
patent: 4762828 (1988-08-01), Georgiev et al.
patent: 4789673 (1988-12-01), Donatsch et al.
patent: 4888347 (1989-12-01), Woodruff et al.
patent: 4940789 (1990-07-01), Childers, Jr. et al.
patent: 5011834 (1991-04-01), Weber et al.
patent: 5196415 (1993-03-01), Monn et al.
Battesby et al., J. Chem. Soc., pp. 1988-1991 (1958).
Brooks et al., J.C.S. Perkin 1, No.21, pp. 2588-2591 (1973).
Brown et al., Tetrahedron Letters, No. 19, pp. 1515-1517 (1969).
Christy et al., J. Org. Chem., 44(18):3117-3127 (1979).
Cioranescu et al., Revue Toumaine de Chimie, 16(10):1555-1566 (1971).
Dobson et al., Tetrahedron Letters, No. 42, pp. 4139-4142 (1967).
Dobson et al., Can. J. Chem., 49:1027-1031 (1971).
Drejer et al., European Journal of Pharmacology, 143:287-290 (1987).
Dygos, J. Heterocyclic Chem., 13:1355-1357 (1976).
Dyke et al., Tetrahedron, 28:2999-4001 (1972).
Evans et al., J. Org. Chem., 44(18):3127-3135 (1979).
Gootjes et al., Arzeim.-Forsch. (Drug Res.), 22(3):632-634 (1972).
Reden et al., Adv. Exp. Med. Biol., 126:69-72 (1980).
Rice et al., J. Org. Chem., 45:601-607 (1980).
Russel et al., Chem. Abstr., 71:285-286, No. 30370d (1969).
Slavik et al., Romeria refracta. Collection Czechoslov. Chem. Commun., 33:4066-4082 (1968).
Takayama et al., Heterocycles, 9(11):1545-1548 (1978).
Vanderlaan et al., J. Org. Chem., 50:743-747 (1985).
Waldmann et al., Ann., 609:125-143 (1957).
Walker et al., J. Org. Chem., 36(3):466-478 (1971).
Weber et al., Chem. Abstr., 115:76, No. 106019w (1991).
The Merck Manual, 15th ed. (1987), Berkow, M.D. editor, 2399-2400.
Remington's Pharmaceutical Sciences, 18th ed. (1990), pp. 625-628, 632.
Cecil Textbook of Medicine, 19th edition, Wyngaarden, M.D. editor, pp. 2075-2078, 2135-2136, 2141-2142 (1992).
Physicians' Guide To Rare Diseases, Thoene, M.D. editor, pp. 55-56 (1992).
Barmettler Peter
Keana John F. W.
Weber Eckard
Berch Mark L.
Conlin David G.
Corless Peter F.
Kifle Bruck
State of Oregon acting by and through the Oregon State Board of
LandOfFree
PCP receptor ligands and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PCP receptor ligands and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PCP receptor ligands and the use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1565802